Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

41.90USD
17 Aug 2018
Change (% chg)

$-0.75 (-1.76%)
Prev Close
$42.65
Open
$42.85
Day's High
$42.85
Day's Low
$41.60
Volume
139,690
Avg. Vol
225,678
52-wk High
$136.90
52-wk Low
$41.30

Select another date:

Fri, Jun 29 2018

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc  on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech gets EU panel nod for breast cancer drug

June 29 Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

UPDATE 1-Puma Biotech says Europe likely to approve breast cancer drug

June 26 Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

Former Puma Biotech executive gets U.S. prison term for insider trading

BOSTON A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing.

Former Puma Biotech exec gets U.S. prison term for insider trading

BOSTON, June 20 A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing.

BRIEF-Puma Biotechnology Q1 Loss Per Share $0.65

* PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib

* PUMA BIOTECHNOLOGY SAYS ‍GIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB Source text for Eikon: (http://bit.ly/2G6kIc2) Further company coverage:

Select another date: